Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (14)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Canis, F.
Right arrow Articles by Courcol, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Canis, F.
Right arrow Articles by Courcol, R. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy, Vol 39, 431-433, Copyright © 1997 by The British Society for Antimicrobial Chemotherapy

JOURNAL ARTICLE

Pharmacokinetics and bronchial diffusion of single daily dose amikacin in cystic fibrosis patients

F Canis, MO Husson, D Turck, P Vic, V Launay, S Ategbo, A Vincent and RJ Courcol
Laboratoire de Bacteriologie-Hygiene, Centre Hospitalier Regional et Universitaire, Lille, France.

A single daily dose of amikacin 35 mg/kg by i.v. infusion over 30 min in 18 cystic fibrosis patients achieved mean serum peak and trough concentrations of 121.4 mg/L (+/- 37.3) and 0.88 mg/L (+/- 0.62), respectively. Pharmacokinetic parameters and bronchial diffusion of amikacin showed marked inter-patient variability. The highest concentrations in sputum were obtained at 2 h (10.95 +/- 7.55 mg/L) and decreased slowly to reach a mean concentration of 2.14 mg/L (range 0.2- 3.8 mg/L) just before the following infusion. An increase in the body clearance of amikacin and a decrease in the volume of distribution according to age were observed.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
R. Greendyke and T. F. Byrd
Differential Antibiotic Susceptibility of Mycobacterium abscessus Variants in Biofilms and Macrophages Compared to That of Planktonic Bacteria
Antimicrob. Agents Chemother., June 1, 2008; 52(6): 2019 - 2026.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
A. Aminimanizani, P. M. Beringer, J. Kang, L. Tsang, R. W. Jelliffe, and B. J. Shapiro
Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis
J. Antimicrob. Chemother., October 1, 2002; 50(4): 553 - 559.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
A. Whitehead, S.P. Conway, C. Etherington, N.A. Caldwell, N. Setchfield, and S. Bogle
Once-daily tobramycin in the treatment of adult patients with cystic fibrosis
Eur. Respir. J., February 1, 2002; 19(2): 303 - 309.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
P. M. Beringer, A. A. T. M. M. Vinks, R. W. Jelliffe, and B. J. Shapiro
Pharmacokinetics of Tobramycin in Adults with Cystic Fibrosis: Implications for Once-Daily Administration
Antimicrob. Agents Chemother., April 1, 2000; 44(4): 809 - 813.
[Abstract] [Full Text]

Home page
 Clin. Chem.Home page
C. A. Hammett-Stabler and T. Johns
Laboratory guidelines for monitoring of antimicrobial drugs
Clin. Chem., May 1, 1998; 44(5): 1129 - 1140.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.